Injection vehicle for polymer-based formulations
First Claim
1. A kit comprising:
- (a) an injection vehicle comprising hyaluronic acid or sodium hyaluronate dissolved in a physiological buffer at a concentration of about 0.01 to about 3 percent weight per volume; and
(b) particles comprising;
(i) a first component that is a biologically active agent; and
(ii) a second component that is a biocompatible polymeric matrix;
wherein (a) and (b) are dispersed in the same or separate containers adapted for simultaneous administration of (a) and (b) to an animal,wherein concentration of the particles when combined with the injection vehicle is about 100 to about 500 mg per mL of an injectable formulation formed by combining the injection vehicle and the particles.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention provides injection vehicles suitable for administering particulate suspensions, such as polymer-based formulations, as well as associated pharmaceutical formulations, articles of manufacture, and kits. Other aspects of the invention included methods for producing and administering pharmaceutical formulations. The injection vehicles of the invention are superior to conventional injection vehicles in that they include a pseudoplastic composition that improves injectability, which facilitates delivery of the desired dose. The injection vehicles of the invention also allow the use of smaller-bore needles than are usually necessary to inject polymer-based formulations, reducing the pain associated with injection of such formulations.
58 Citations
22 Claims
-
1. A kit comprising:
-
(a) an injection vehicle comprising hyaluronic acid or sodium hyaluronate dissolved in a physiological buffer at a concentration of about 0.01 to about 3 percent weight per volume; and (b) particles comprising; (i) a first component that is a biologically active agent; and (ii) a second component that is a biocompatible polymeric matrix; wherein (a) and (b) are dispersed in the same or separate containers adapted for simultaneous administration of (a) and (b) to an animal, wherein concentration of the particles when combined with the injection vehicle is about 100 to about 500 mg per mL of an injectable formulation formed by combining the injection vehicle and the particles. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)
-
Specification